In this present research, calcium phosphate cement (CPC) paste was prepared by combining cement liquids comprised of 4 wt-% disodium hydrogen orthophosphate with cement powders that consisted of β-tricalcium phosphate and monocalcium phosphate monohydrate. In the in vitrostudy, the release of gentamicin sulphate (GS) from standard cylindrical samples of the prepared CPC immersion in phosphate buffered saline solution was measured by high performance liquid chromatography test over a period of time. In addition, as a representative for biomedical properties, setting time, injectability and compressive strength were measured in order to detect changes when mixing CPC with GS. In addition, the pH values of the phosphate buffered saline solution containing samples descended gradually until reaching equilibrium pH. Overall, the results from in vitro release study showed that it reached its maximum level, which was 35% of the initial value of the GS on day 15, suggesting no irreversible binding occurred between the cement paste and the antibiotic.
BakshD, DaviesJE, KimS: ‘Three-dimensional matrices of calciumpolyphosphates support bone growth in vitro and in vivo’, J.Mater. Sci., Mater. Med., 1998, 9, 743–748.
5.
KurashinaK, KuritaH, HiranoM, KotaniA, KleinCP, de GrootK: ‘In vivo study of calcium phosphatecements: implantation of an alpha-tricalcium phosphate/dicalcium phosphatedibasic/tetracalcium phosphate monoxide cement paste’, Biomaterials, 1997, 18, 539–543.
6.
ZamanianA, MoztarzadehF, KordestaniS, HesarakiS, TahririMR: ‘Novel calcium hydroxide/nanohydroxyapatitecomposites for dental applications: in vitro study’, Adv.Appl. Ceram., 2010, 109, 440–445.
ApeltD, TheissF, El-WarrakAO, ZlinszkyK, Bettschart-WolfisbergerR, BohnerM, MatterS, AuerJA, von RechenbergB: ‘In vivo behavior of three differentinjectable hydraulic calcium phosphate cements’, Biomaterials, 2004, 25, 1439–1451.
10.
JansenJA, de RuijterJE, SchaekenHG, der WaerdenJPCvan, PlanellJA, DriessensFC: ‘Evaluation of tricalcium phosphate/hydroxyapatitecement for tooth replacement: an experimental anomaly study’, J.Mater. Sci., Mater. Med., 1995, 6, 653–657.
11.
FriedmanCD, CostantinoPD, TakagiS, ChowLC: ‘BoneSource™ hydroxyapatitecement: a novel biomaterial for craniofacial skeletal tissue engineering andreconstruction’, J. Biomed. Mater. Res. A, 1998, 43A, 428–432.
12.
LarssonS, BauerTW: ‘Use of injectable calcium phosphatecement for fracture fixation – a review’, Clin.Orthop. Relat. Res., 2002, 395, 23–32.
13.
OomsEM, WolkeJGC, de HeuvelMTvan, JeschkeB, JansenJA: ‘Histological evaluation of the boneresponse to calcium phosphate cement implanted in cortical bone’, Biomaterials, 2003, 24, 989–1000.
14.
GinebraM, TraykovaT, PlanellJA: ‘Calcium phosphate cements: competitivedrug carriers for the musculoskeletal system?’ Biomaterials, 2006, 27, 2171–2177.
15.
ArkfieldDG, RubensteinE: ‘Quest for the Holy Grail to cure arthritisand osteoporosis: emphasis on bone drug delivery systems’, Adv.Drug Delivery Rev., 2005, 57, 934–944.
16.
GinebraMP, TraykovaT, PlanellJA: ‘Calcium phosphate cements as bone drugdelivery systems: a review’, J. Controlled Release, 2006, 113, 102–110.
17.
BrownPW, ChowLC: ‘A calcium phosphate water setting cement.Cements research progress’, Proc. AmericanCeramics Society, Cocoa Beach, FL, USA, 1986, ACS, 352–379.
OhuraK, BohnerM, HardouinP, LemaitreJ, PasquierG, FlautreB: ‘Resorption of, and bone formation from,new beta-tricalcium phosphate-monocalcium phosphate cements: an in vivo study’, J.Biomed. Mater. Res., 1996, 30, 193–200.
27.
LemaitreJ, MirtchiAA, MortierA: ‘Calcium phosphate cements for medicaluse: state of the art and perspectives of development’, Sil.Ind. Ceram. Sci., 1987, 10, 141–146.
GbureckU, ProbstJ, ThullR: ‘Surface properties of calcium phosphateparticles for self-setting bone cements’, Biomol.Eng., 2002, 19, 51–55.
32.
MarksKE, NelsonCL, LautenschlagerEP: ‘Antibiotic-impregnated acrylic bonecement’, J. Bone Joint Surg. Am., 1976, 58, 358–364.
33.
WalenkampGH, KleijnLL, de LeeuwM: ‘Osteomyelitis treated with gentamicin-PMMAbeads: 100 patients followed for 1–12 years’, ActaOrthop. Scand., 1998, 69, 518–522.
34.
HillJ, KlenermanL, TrusteyS, BlowersR: ‘Diffusion of antibiotics from acrylicbone-cement in vitro’, J. Bone Joint Surg. Br., 1977, 59, 197–199.
35.
FaberC, StallmannHP, LyaruuDM, JoostenU, von EiffC, AmerongenAvan Nieuw, WuismanPI: ‘Comparable efficacies of the antimicrobialpeptide human lactoferrin 1–11 and gentamicin in a chronic methicillin-resistantstaphylococcus aureus osteomyelitis model’, Antimicrob.Agents Chemother., 2005, 49, 2438–2444.
36.
LangerR: ‘Drug delivery and targeting’, Nature, 1998, 392, 5–10.
37.
WuY, MackayJA, McdanielJR, ChilkotiA, ClarkRL: ‘Fabrication of elastin-like polypeptidenanoparticles for drug delivery by electrospraying’, Biomacromolecules, 2009, 10, 19–24.
XuY, SkotakM, HannaM: ‘Electrospray encapsulation of water-solubleprotein with polylactide. I. Effects of formulations and process on morphologyand particle size’, J. Microencapsulation, 2006, 23, 69–78.
40.
PancholiK, AhrasN, StrideE, EdirisingheM: ‘Novel electrohydrodynamic preparationof porous chitosan particles for drug delivery’, J.Mater. Sci., Mater. Med., 2009, 20, 917–923.
41.
EnayatiM, AhmadZ, StrideE, EdirisingheM: ‘Size mapping of electric field-assistedproduction of polycaprolactone particles’, Curr.Pharm. Biotechnol., 2009, 10, 600–608.
42.
JoseGR, ParkK: ‘Oral drug delivery: prospects and challenges’, J.Drug Delivery Sci. Technol., 2004, 4, 1–7.
43.
LangerR: ‘Perspectives: drug delivery–drugson target’, Science, 2001, 293, 58–59.
BajajA, DesaiM: ‘Challenges and strategies in noveldrug delivery technologies’, Pharma Times, 2006, 38, 12–16.
46.
EnayatiM, ChangMW, BragmanF, EdirisingheM, StrideE: ‘Electrohydrodynamic preparation ofparticles, capsules and bubbles for biomedical engineering applications, ColloidsSurf. A, 2011, 382A, 154–164.
47.
MathiowitzE, ed (ed.): ‘Encyclopaedia of controlleddrug delivery;1999, New York, JohnWiley.
48.
RatnerBD, HoffmanAS, SchoenFJ, Lemons (eds.)JE: ‘Biomaterials science. An introductionto materials in medicine’, 2nd edn; 2004, SanDiego, CA, Academic Press.
49.
HiguchiT: ‘Mechanisms of sustained action mediation:theoretical analysis of rate of release of solid drugs dispersed in solidmatrices’, J. Pharm. Sci., 1963, 52, 1143–1149.
50.
BalmayorER, BaranET, AzevedoaHS, ReisRL: ‘Injectable biodegradable starch/chitosandelivery system for the sustained release of gentamicin to treat bone infections’, Carbohyd.Polym., 2011, to be published.
51.
BohnerM, Van LanduytP, MerkleHP, LemaitreJ: ‘Composition effects on the pH of ahydraulic calcium phosphate cement’, J. Mater.Sci., Mater. Med., 1997, 8, 675–681.
52.
BohnerM, LemaitreJ, RingTA: Effects of sulfate, pyrophosphate, and citrateions on the physicochemical properties of cements made of β-tricalciumphosphate-phosphoric acid–water mixtures, J.Am. Ceram. Soc., 1996, 79, 1427–1434.
